目的：观察阿托伐他汀联合依折麦布治疗急性冠脉综合征的临床疗效及安全性。方法将94例患者随机分为观察组和对照组，每组47例。对照组给予阿托伐他汀钙片20 mg / d，观察组联合给予依折麦布10 mg / d，均睡前服用，疗程4周。检测患者治疗前后血脂及超敏 C 反应蛋白（hs - CRP）水平，比较两组患者的近期血脂达标率及临床安全性。结果治疗结束后，两组血清总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL - C）和 hs - CRP 水平均明显降低（ P ＜0.05），观察组各项指标改善均显著优于对照组（ P ＜0.05）；与治疗前水平相比，观察组治疗后 HDL - C 明显升高，比对照组升高更明显（ P ＜0.05），对照组治疗后 HDL - C 虽有所升高但无明显差异（ P ＞0.05）；观察组患者血脂达标率为53.19％，明显高于对照组的27.66％（ P ＜0.05）；观察组心绞痛及心肌梗死再发率明显低于对照组（ P ＜0.05），其他不良反应组间比较无明显差异（ P ＞0.05）。结论阿托伐他汀联合依折麦布治疗急性冠脉综合征临床疗效确切，可显著提高患者血脂达标率，减少心血管事件的发生率，具有良好的安全性。%Objective To observe the clinical efficacy and safety of atorvastatin combined with ezetimibe for treating acute coronary syn-drome. Methods 94 cases of acute coronary syndrome were randomly divided into the observation group and the control group with 47 cases in each group. The patients in the control group were given atorvastatin 20 mg / d,while the patients in the observation group re-ceived atorvastatin 20mg plus ezetimibe 10 mg / d by oral administration before sleeping. All patients were treated for 4 weeks. The plas-ma lipids and hypersensitive C - reactive protein(hs - CRP)before and after treatment were detected. The short term reaching standard rate of blood lipids and the clinical safety were compared between the groups. Results After therapy,the TC,TG,LDL - C and hs -CRP levels in the two groups were significantly reduced( P 0. 05);the reaching standard rate of blood lipids in the observation group was 53. 19% ,which was significantly higher than 27. 66% in the control group ( P 0. 05). Conclusion Atorvastatin combined with ezetimibe has the definite effect in treating acute coronary syndrome,can significantly increase the reaching standard rate of blood lipids and reduce the occurrence rate of cardiovascular events with good safety.
展开▼
